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PPioglitazone Improves Myocardial
Blood Flow and Glucose Utilization
in Nondiabetic Patients With Combined Hyperlipidemia
A Randomized, Double-Blind, Placebo-Controlled Study
Rossi P. Naoumova, MD, PHD, FAHA, MRCP,* Heiko Kindler, MD, MRCP,*
Lucia Leccisotti, MD,*† Marco Mongillo, MD, PHD,* Muhammad T. Khan, MD, FRCS,*
Clare Neuwirth, RN,* Mary Seed, MA, DM, FRCPATH, FREP,‡ Paul Holvoet, PHD, FAHA,§
John Betteridge, PHD, MD, FAHA, FRCP, Paolo G. Camici, MD, FESC, FACC, FAHA, FRCP*#
London, United Kingdom; Rome, Italy; and Leuven, Belgium
Objectives This study’s aim was to examine whether treatment with pioglitazone, added to conventional lipid-lowering ther-
apy, would improve myocardial glucose utilization (MGU) and blood flow (MBF) in nondiabetic patients with fa-
milial combined hyperlipidemia (FCHL).
Background Thiazolidinediones were found to improve insulin sensitivity and MGU in type 2 diabetes and MBF in Mexican
Americans with insulin resistance. Familial combined hyperlipidemia is a complex genetic disorder conferring a
high risk of premature coronary artery disease, characterized by high serum cholesterol and/or triglyceride, low
high-density lipoprotein (HDL) cholesterol, and insulin resistance.
Methods We undertook a randomized, double-blind, placebo-controlled study in 26 patients with FCHL, treated with piogli-
tazone or matching placebo 30 mg daily for 4 weeks, followed by 45 mg daily for 12 weeks. Positron emission
tomography was used to measure MBF at rest and during adenosine-induced hyperemia and MGU during eugly-
cemic hyperinsulinemic clamp at baseline and after treatment.
Results Whereas no change was observed in the placebo group after treatment, patients receiving pioglitazone showed
a significant increase in whole body glucose disposal (3.93  1.59 mg/kg/min to 5.24  1.65 mg/kg/min; p 
0.004) and MGU (0.62  0.26 mol/g/min to 0.81  0.14 mol/g/min; p  0.0007), accompanied by a signif-
icant improvement in resting MBF (1.11  0.20 ml/min/g to 1.25  0.21 ml/min/g; p  0.008). Furthermore,
in the pioglitazone group HDL cholesterol (28%; p  0.003) and adiponectin (156.2%; p  0.0001) were
increased and plasma insulin (35%; p  0.017) was reduced.
Conclusions In patients with FCHL treated with conventional lipid-lowering therapy, the addition of pioglitazone led to signifi-
cant improvements in MGU and MBF, with a favorable effect on blood lipid and metabolic parameters. (A study
to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood
flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemia; http://www.controlled-
trials.com/mrct/trial/230761/ISRCTN78563659; ISRCTN78563659) (J Am Coll Cardiol 2007;50:2051–8)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.070s
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familial combined hyperlipidemia (FCHL) (OMIM
4250) is a common genetically heterogeneous disorder that
ffects 1% to 3% of the Western population and confers a
ubstantially increased risk of premature coronary artery disease
CAD) (1–3). The FCHL phenotype is characterized by high
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nd Lung Institute, Imperial College, Hammersmith Hospital, London, United King-
om; †Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Rome,
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ardiovascular Diseases, Faculty of Medicine, Katholieke Universiteit Leuven, Leuven, aerum levels of cholesterol and/or triglyceride (4), low high-
ensity lipoprotein (HDL) cholesterol, high serum apoli-
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density lipoproteins (LDL) as well
as by insulin resistance (5–7).
Earlier studies using positron
emission tomography (PET) have
demonstrated that subjects at an
increased risk of developing CAD,
such as smokers (8) and those with
hyperlipidemia (9), often have
abnormal myocardial blood flow
(MBF) and coronary flow reserve
(CFR) despite normal coronary
angiograms. The latter has been
interpreted as evidence of coro-
nary microvascular dysfunction
which might precede develop-
ment of more typical CAD. The
FCHL phenotype, however, is
associated with insulin resis-
tance, and the lipid abnormalities
in this condition are therefore
similar to those seen in patients
with metabolic syndrome and
type 2 diabetes (3).
The complex nature of FCHL,
involving genetic and environmen-
tal factors, and the multiple lipid
abnormalities that characterize
CHL make this condition difficult to treat, frequently
ecessitating combination drug therapy with different
lasses of lipid-lowering agents. Given the association of
CHL with insulin resistance, there is a potential for
mprovement of the lipid parameters with thiazo-
idinediones, which activate the peroxisome proliferator-
ctivated receptor- on the nuclear membrane and improve
ostreceptor insulin signaling and insulin sensitivity (10).
ndeed, thiazolidinediones have been shown to have a
avorable effect on some serum lipid parameters in patients
ith diabetes (11–13) and in nondiabetic patients with
ypertension (14). Thiazolidinediones have been reported
o improve endothelial function (15) and myocardial glucose
tilization (MGU) (16,17) in patients with type 2 diabetes.
owever, treatment with pioglitazone had no effect on
BF in patients with insulin-treated type 2 diabetes (17),
lthough thiazolidinediones did improve coronary vasomo-
or abnormalities in Mexican Americans with insulin resis-
ance (18).
We hypothesized that treatment with thiazolidinediones,
dded to conventional management, might improve both
hole body and myocardial insulin sensitivity and MBF in
CHL patients. Therefore, we undertook a randomized,
ouble-blind, placebo-controlled study in FCHL patients
sing PET to measure MGU, MBF, and CFR at baseline
nd after 4 months of treatment with the thiazolidinedione
Abbreviations
and Acronyms
BMI  body mass index
CAD  coronary artery
disease
CFR  coronary flow
reserve
FCHL  familial combined
hyperlipidemia
FDG 
2-[18F]fluoro-2-deoxy-D-glucose
H2
15O  oxygen-15–labeled
water
HDL  high-density
lipoprotein cholesterol
LDL  low-density
lipoprotein cholesterol
M  whole body glucose
disposal
MBF  myocardial blood
flow
MGU  myocardial glucose
utilization
PAI  plasminogen
activator inhibitor
PET  positron emission
tomographyioglitazone. dethods
atients. Index patients with FCHL from our well char-
cterized cohort were invited to participate in the study. A
escription of the FCHL cohort and recruitment and
iagnostic criteria have been previously published in detail
3,19). Patients were eligible to participate in the present
tudy if despite lipid-lowering medication with a statin
with or without other conventional lipid-lowering agents) 1
r more of their serum lipid parameters remained above
arget levels (total serum cholesterol 5 mmol/l, triglycer-
des 1.7 mmol/l, HDL cholesterol 1.0 mmol/l, or total
holesterol to HDL cholesterol ratio 5.0). Patients were
eemed to have CAD based on clinical evidence (i.e.,
oronary angiography in symptomatic patients, history of
revious myocardial infarction, and coronary revasculariza-
ion). The patients who were designated CAD negative
ere asymptomatic, with no chest pain history and normal
esting electrocardiograms, and they did not have coronary
ngiography.
Patients were excluded from the study for any of the
ollowing: type 1 or type 2 diabetes, obesity, abnormal liver
unction tests (defined as alanine aminotransferase 2.5
imes the upper limit of the reference range), and significant
enal impairment (defined as creatinine 135 mol/l).
A total of 32 British Caucasians with FCHL were
nrolled in the study, and 26 completed the study according
o the protocol. Four patients did not meet the recruitment
riteria, and 2 patients refused to have the PET scan
epeated at the end of the study period and discontinued
aking the medication. All 26 patients who completed the
tudy were included in the analysis.
All of the patients attended the same lipid clinic for at
east 2 years and had been on stable medical therapy and diet
or at least 3 months before inclusion in the study. Therapy
nd dietary habits remained the same during the trial
eriod.
All patients gave written informed consent before partic-
pation, and the study protocol was approved by the Re-
earch Ethics Committees of the 2 participating hospitals
Hammersmith Hospital, Imperial College, and University
ollege Hospitals, University College London) and by the
.K. Administration of Radioactive Substances Advisory
ommittee. The study was conducted according to the
uidelines of the Declaration of Helsinki.
The study was registered in a public access database for
ontrolled clinical trials (register number ISRCTN78563659).
tudy design and protocol. The study protocol is shown
n Figure 1. The study was designed as a 2-center double-
lind randomized placebo-controlled trial; patients who met
he inclusion and exclusion criteria at visit 1 were randomly
llocated to receive treatment with pioglitazone or placebo
rom visit 2 and treated for a period of 16 weeks. For the
rst 4 weeks patients received 30 mg pioglitazone or placebo
aily (both manufactured by Takeda, Osaka, Japan), and the
osage was increased to 45 mg daily for the rest of the study.
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November 20, 2007:2051–8 Pioglitazone Improves Cardiac Metabolism and Flowf adverse events were observed, patients remained on 30
g. A PET scan was performed twice: before and after
reatment.
All patients refrained from caffeine-containing beverages
or the 12 h preceding the PET studies. The 4 smokers
ontinued to smoke throughout the study although they did
ot smoke in the 2 to 3 h preceding the PET studies when
hey were attended by the investigators. Compliance with
tudy medication was calculated based on the dispensing
nd return of study medication tablets and showed that the
ean dose was 28.3  3.58 mg during the first 4 weeks and
1.5  6.5 mg daily for the rest of the study, which
epresents 94% and 92% compliance, respectively.
aboratory analyses. All blood samples were obtained
fter a 12-h fast at week 0 and again at week 16. Total
holesterol, triglyceride, and HDL cholesterol serum levels,
lasma glucose, and hemoglobin A1c were determined by
utomated methods using commercial kits and interassay
ontrols. The LDL cholesterol levels were calculated from
he standard formula: LDL cholesterol  total cholesterol 
HDL cholesterol [triglycerides/2.2]). Serum lipoprotein (a)
as measured using an automated immunoturbidimetric assay
Beckman Instruments, Galway, Ireland). Plasma insulin was
nalyzed using an established radioimmunoassay (20). All
amples were frozen and subsequently assayed in duplicate
n a single occasion. The detection limit of the assay was 6
mol/l, and the intra-assay coefficient of variation was 5.4%. As
proxy for small dense LDL particles, we used the triglycerides
o HDL cholesterol molar ratio, which is known as the
therogenic index of plasma (21,22). Nonesterified fatty acids
NEFA) were measured in serum using the NEFA C, ACS-
COD Method (Wako Chemicals, Neuss, Germany). Plasma
lasminogen activator inhibitor (PAI)-1 was determined by
nzyme-linked immunosorbent assay (ELISA) (Hyphen
ioMed, Neuville sur Oise, France). Plasma levels of oxidized
DL were measured in an mAB-4E6–based competition
LISA (Mercodia, Uppsala, Sweden) and adiponectin plasma
evels in the Quantikine ELISA (R&D Systems, Abingdon,
Figure 1 Diagram Depicting the Study Protocol With the Relati
Thin arrows  hospital visits when blood pressure, pulse, and body weight were c
emission tomography (PET) scans; thick line  study medication (placebo/pioglitanited Kingdom). iET. REGIONAL MYOCARDIAL PERFUSION. The PET
tudies were performed in a 3-dimensional imaging mode
or oxygen-15–labeled water (H2
15O) and a 2-dimensional
maging mode for 2-[18F]fluoro-2-deoxy-D-glucose (FDG)
sing a 962 (HR) scanner (Siemens, Knoxville, Tennes-
ee) after an overnight fast and abstinence from caffeine-
ontaining beverages for at least 24 h. A 20-min transmis-
ion scan was performed and used for subsequent
ttenuation correction of all emission scans. The blood pool
as then imaged using oxygen-15–labeled carbon monoxide
C15O) (3 MBq/ml at 500 ml/min for 4 min). A 9-min
ingle-frame emission scan was initiated 1 min after the end
f the C15O inhalation to allow for equilibration (23). After
llowing 10 min for the decay of 15O radioactivity, resting
nd hyperemic (intravenous adenosine, 140 g/kg/min over
min) MBF were measured using H2
15O (185 MBq),
njected intravenously over 20 s at a rate of 10 ml/min with
ushing for a further 2 min, as previously described (23).
he following scanning protocol was used: 1  30 s
background), 1  20 s, 14  5 s, 3  10 s, 4  20 s, and
 30 s, for a total scanning time of 350 s.
EGIONAL MGU. To measure whole body glucose disposal
M) and provide a standardized metabolic milieu for the
easurement of MGU, a hyperinsulinemic-euglycemic
lamp was performed as previously described (23–25). After
t least 90 min of hyperinsulinemia, 185 MBq FDG was
njected over a 2-min period and a 37-frame dynamic PET
can acquired over 50 min (1 30 s [background], 12 10 s,
 20 s, 4  30 s, 5  60 s, 8  150 s, 4  300 s) (25).
ET DATA ANALYSIS. The sinograms were corrected for
ttenuation and reconstructed using standard algorithms.
ubsequent images were analyzed with Matlab (Mathworks,
atick, Massachusetts) software. Myocardial images, for
he definition of regions of interest (ROIs), were generated
irectly from the dynamic H2
15O, as previously reported
26). Sixteen ROIs were drawn within the left ventricular
yocardium (27) and projected onto the dynamic H2
15O
mings
d and fasting blood sample obtained; thick arrows  positron
with randomization at visit 2; stethoscope  physical examination.ve Ti
hecke
zone)mages to obtain tissue activity curves. A separate set of
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Pioglitazone Improves Cardiac Metabolism and Flow November 20, 2007:2051–8OIs was defined for the right ventricular cavity and the left
trium. Myocardial and blood time-activity curves were
hen generated from the dynamic image and fitted to a
ingle-tissue compartment tracer kinetic model to give
alues of MBF (ml/min/g) (28). The CFR was calculated as
he ratio of MBF during hyperemia to MBF at rest (29).
oronary resistance was calculated as mean blood pressure
ivided by MBF (whole left ventricle).
Tissue FDG time-activity curves were analyzed by a
inearized approach using the same 16 myocardial ROIs
efined for H2
15O (30,31). The MGU data were corrected
or partial volume effect using extravascular volume mea-
urement, obtained from the C15O and transmission scans,
s previously described (25). The final MGU values are
xpressed as mol/g/min.
tatistical methods. Statistical analysis was performed in
he 26 patients who completed the study. All data are given
s least-squares mean  SEM. Change from baseline data
as tested by analysis of covariance with factor treatment
placebo or pioglitazone) taken into account. The baseline
alue of the variable was included as a covariate to control
or differences at baseline between study groups. A p value
f 0.05 was considered to be statistically significant.
esults
aseline characteristics. The clinical characteristics of the
atients in the placebo and pioglitazone groups and their
edication are presented in Table 1. The mean age of the
ioglitazone group was lower compared with the placebo
roup (p  0.05) and there were more current smokers in
he active treatment group, whereas the 2 groups were
imilar regarding concomitant medication. There was also
ifference with regard to body mass index (BMI) between
he placebo and pioglitazone group (26.47 2.19 kg/m2 vs.
haracteristics of the Study Subjects (n  26)
Table 1 Characteristics of the Study Subjects (n  26)
Placebo Pioglitazone
n 12 14
Gender (M/F) 11/1 13/1
Age (mean yrs  SD) 55  6* 50  6
Current smokers 0 4
CAD 5 3
Medications
ACE inhibitors 5 8
Beta-blockers 4 2
Calcium-channel blockers 4 2
ASA 8 9
Nitrates 1 0
Lipid-lowering
Statins 12 14
Fibrate 5 6
Omega-3 fatty acids 2 4
Ezetimibe 1 1
p  0.05 versus pioglitazone group.c
ACE  angiotensin-converting enzyme; ASA  acetylsalicylic acid; CAD  coronary artery
isease.8.92  1.79 kg/m2, respectively; p  0.05). All of the
tudy patients were on treatment with statins. The patients
rom the pioglitazone and placebo groups were on treatment
ainly with atorvastatin (64% and 67% of the patients from
he 2 groups, respectively; p  NS). The median dose of
torvastatin was 20 mg daily for both groups. Single patients
rom both groups were treated with pravastatin, simvastatin,
nd rosuvastatin on similar doses. Combination of statin
nd fibrate was used in 43% of the patients from the
ioglitazone group and 42% of the patients from the placebo
roup. The median dose of fibrate for both treatment
roups was 267 mg daily. The lipid-lowering medication for
ll patients remained unchanged during the study.
ffect of pioglitazone treatment on clinical and labora-
ory parameters. The effect of 16 weeks’ treatment on
aboratory parameters is summarized in Table 2. Pioglita-
one therapy significantly increased BMI (from 28.92 
.79 kg/m2 to 29.38  1.71 kg/m2; p  0.05), whereas no
hange occurred in the placebo group (from 26.47  2.19
g/m2 to 26.60  2.37 kg/m2). A significant increase in
DL cholesterol, LDL cholesterol, and adiponectin and a
eduction in plasma insulin were observed in pioglitazone
roup compared with the placebo group with no change in
otal cholesterol, triglycerides, atherogenic index of plasma,
xidized LDL, NEFA, lipoprotein (a), plasma glucose, or
emoglobin A1c. In addition, a significant reduction in total
holesterol to HDL cholesterol ratio (p  0.04) and PAI-1
p  0.01) was observed in the pioglitazone group after
reatment (within-treatment effect).
ffect of the treatment on PET findings. A significant
ncrease in M and MGU was observed in the pioglitazone
roup compared with the placebo group (Table 3, Fig. 2). In
ddition, patients treated with pioglitazone had a significant
mprovement in resting MBF and a reduction in resting
oronary resistance (Table 3) compared with the placebo
roup. And hyperemic MBF increased significantly (p 
.01) in the pioglitazone group after treatment (within-
reatment effect) (Fig. 3).
iscussion
he major novel findings in this study are that the addition
f pioglitazone to conventional lipid-lowering therapy in
ondiabetic FCHL patients leads to: 1) additional beneficial
ffects on serum lipid and metabolic parameters beyond
hose achieved with standard lipid-lowering therapy; and 2)
ignificant improvement in M, MGU, and MBF.
ffects of pioglitazone on blood parameters. The insulin-
ensitizing thiazolidinediones have been tested as experi-
ental therapies with variable success (10) in other groups
f patients with nondiabetic insulin resistance, such as
onalcoholic fatty liver disease (32), polycystic ovary syn-
rome (33), hypertension (14), and lipodystrophies (34,35).
atients with FCHL have numerous metabolic abnormali-
ies similar to those in the metabolic syndrome and require
omplex management. The addition of pioglitazone to the
t
w
c
c
a
o
t
l
l
p
c
c
i
f
p
c
l
p
E
b
p
a
e
l
o
r
A
p
M
s
c
p
w
m
a
(
t
E
D
nfiden
L
E
D
e
2055JACC Vol. 50, No. 21, 2007 Naoumova et al.
November 20, 2007:2051–8 Pioglitazone Improves Cardiac Metabolism and Flowherapeutic regimen of the present FCHL patients, all of
hom were on statins and nearly one-half of them on a
ombination with a fibrate, led to further changes in HDL
holesterol, total cholesterol to HDL cholesterol ratio,
diponectin, plasma insulin, and PAI-1. The lack of effect
f pioglitazone on levels of oxidized LDL could be due to
he long-term statin treatment, which is associated with
owering of oxidized LDL even beyond LDL cholesterol
owering (36,37).
Abbink et al. (38) observed that treatment of FCHL
atients with pioglitazone alone led to advantageous
hanges of the LDL subfraction profile, but no other
hanges in the lipid-profile or the flow-mediated dilatation
n the brachial artery were documented. These differences
rom the present study may be due to the smaller dose of
ioglitazone used by Abbinket al. (38) and the lack of
oncomitant conventional lipid-lowering medication; the
atter might have facilitated and/or augmented the effects of
ioglitazone observed by us.
ffect of the Treatment (16 Weeks) on Clinical and Laboratory Par
Table 2 Effect of the Treatment (16 Weeks) on Clinical and La
Placebo (n  12)
Baseline Treatment B
Total cholesterol (mmol/l) 4.77 0.28 4.87 0.25 4.9
Triglycerides (mmol/l) 1.63 0.46 1.79 0.14 2.9
HDL cholesterol (mmol/l) 1.21 0.06 1.16 0.05 1.0
AIP 1.41 0.47 1.53 0.15 2.8
Total cholesterol:HDL cholesterol 3.98 0.28 4.25 0.23 4.6
LDL cholesterol (mmol/l) 2.81 0.23 2.82 0.17 2.6
Oxidized LDL (U/l) 80.83 5.97 77.23 4.72 87.4
Adiponectin (g/ml) 4.66 0.98 4.13 1.10 4.5
NEFA (mmol/l) 0.87 0.10 0.73 0.13 0.7
Lp(a) (mg/dl) 50.17 12.66 43.45 4.04 36.4
Glucose (mmol/l) 5.58 0.16 4.83 0.13 4.9
HbA1c (%) 5.76 0.12 5.79 0.06 5.5
Insulin (pmol/l) 93.77 11.48 95.94 11.02 85.7
PAI-1 (ng/ml) 18.45 4.97 15.35 3.97 21.3
ata are presented as least-squares mean value  SEM.
AIP  atherogenic index of plasma, or triglycerides to HDL cholesterol molar ratio; CI  co
p(a)  lipoprotein (a); NEFA  nonesterified fatty acids; PAI  plasminogen activator inhibitor.
ffect of the Treatment (16 Weeks) on Hemodynamic Data and PE
Table 3 Effect of the Treatment (16 Weeks) on Hemodynamic
Placebo (n  12)
Baseline Treatment
Systolic blood pressure (mm Hg) 122.42 9.59 126.58 11.44 128
Diastolic blood pressure (mm Hg) 75.08 9.60 77.33 8.39 79
Heart rate (beats/min) 63.33 8.18 65.33 14.02 64
M (mg/kg/min) 4.23 2.11 3.66 1.44 3
MGU (mol/g/min) 0.63 0.25 0.58 0.26 0
Resting MBF (ml/min/g) 1.05 0.21 1.01 0.19 1
Hyperemic MBF (ml/min/g) 2.70 1.03 2.90 1.06 2
CFR (relative value) 2.66 1.11 2.95 1.12 2
Resting CR (mm Hg/ml/min/g) 90.04 20.07 96.19 22.91 88
Minimum CR (mm Hg/ml/min/g) 37.96 17.51 32.75 11.49 41
ata are presented as least-squares mean  SEM.
CFR coronary flow reserve; CI confidence interval; CR coronary resistance; M whole body gluco
mission tomography.ffect of pioglitazone on myocardial metabolism and
lood flow. To our knowledge this is the first study where
ioglitazone was used to investigate its effects on MGU and
bsolute resting and hyperemic MBF simultaneously. Three
arlier studies using PET examined the effect of thiazo-
idinediones on MGU in patients with type 2 diabetes. In
ne study, patients (n  44) were randomized to receive
osiglitazone, metformin, or placebo over a 26-week period.
t the end of the study only rosiglitazone treatment
roduced a significant improvement in M (36%) and
GU (38%), which the authors ascribed to serum NEFA
uppression (39). In a subsequent double-blind placebo-
ontrolled randomized study from the same group, 54
atients with type 2 diabetes and CAD were treated for 16
eeks with rosiglitazone or placebo. Rosiglitazone treat-
ent led to improved MGU in both normal myocardium
nd regions with evidence of exercise-inducible ischemia
16). In a smaller study, 16 patients with insulin-treated
ype 2 diabetes were randomly assigned to 12 weeks’
ers
ory Parameters
litazone (n  14)
Difference 95% CI for Difference p Valuee Treatment
.26 5.30 0.23 0.42 0.28 to 1.13 0.225
.42 1.80 0.13 0.01 0.39 to 0.41 0.940
.06 1.40 0.05 0.24 0.09 to 0.38 0.003
.43 1.38 0.13 0.15 0.59 to 0.28 0.472
.26 3.90 0.21 0.35 1.01 to 0.31 0.287
.23 3.33 0.17 0.51 0.01 to 1.01 0.047
.53 78.94 4.36 1.71 11.67 to 15.09 0.794
.91 11.93 1.01 7.81 4.71 to 10.90 0.0001
.09 0.85 0.12 0.12 0.24 to 0.49 0.496
1.72 36.47 3.74 6.98 18.45 to 4.49 0.220
.15 5.03 0.12 0.21 0.19 to 0.61 0.295
.11 5.70 0.06 0.09 0.26 to 0.08 0.296
0.63 55.07 10.20 38.87 70.0 to7.73 0.017
.60 9.79 3.68 5.55 16.77 to 5.67 0.316
ce interval; Hb  hemoglobin; HDL  high-density lipoprotein; LDL  low-density lipoprotein;
asurements
and PET Measurements
oglitazone (n  14)
Difference 95% CI for Difference p Valueine Treatment
9.11 124.00 10.41 5.92 13.76 to 1.92 0.132
6.43 74.93 7.44 3.77 0.92 to 2.38 0.218
9.33 68.77 7.45 3.02 3.59 to 9.63 0.355
1.59 5.24 1.65 1.67 0.58 to 2.76 0.004
0.26 0.81 0.14 0.24 0.11 to 0.37 0.0007
0.20 1.25 0.21 0.24 0.07 to 0.41 0.008
0.97 3.38 1.02 0.44 0.45 to 1.33 0.318
1.05 2.74 0.88 0.22 0.422 to 0.66 0.608
15.73 74.74 12.61 21.61 36.56 to6.66 0.0065
17.21 27.50 7.45 4.57 12.57 to 3.43 0.249amet
borat
Piog
aselin
8 0
4 0
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hanges in glucose and lipid parameters in the pioglitazone
roup, the study did not demonstrate any significant change
n resting and hyperemic MBF or CFR (17). In a nonran-
omized study in 25 Mexican Americans with evidence of
nsulin resistance, 3 months’ treatment with thiazolidinediones
id not lead to significant changes in resting and dipyridamole-
timulated MBF, although the MBF response to cold pressor
est, which is a marker of endothelium dependent vasodilata-
ion, was significantly improved (18).
The present study is the first in which the effect of
hiazolidinediones on MGU and MBF were tested in the
ame patients simultaneously. In addition to the discussed
ffects on blood parameters, which represent important
ardiovascular risk factors, the results of the present study
rovide novel evidence of a combined effect of pioglitazone
n MGU, MBF, and coronary resistance.
Based on the present results, it is not possible to prove
eyond doubt that the improvement in MBF and coronary
esistance is related to the effects of the drug on lipid and
lucose metabolism, although some parameters which im-
roved after treatment with pioglitazone (e.g., HDL cho-
esterol) are known to affect overall coronary function (9).
revious studies have demonstrated that patients at higher
Figure 2 M and MGU in Placebo and Pioglitazone
Groups at Baseline and After Treatment
After treatment, significant increases in whole body glucose disposal (M) and
myocardial glucose utilization (MGU) were obtained only in the pioglitazone
group. Error bars indicate SEM. *p  0.05 for treatment differences between
the placebo and pioglitazone groups.isk of developing CAD, such as smokers and those withyperlipidemia, have abnormalities of coronary microvascu-
ar function which can improve after correction of the risk
actors (40). Therefore, it is possible to speculate that the
hange in MBF and coronary resistance following pioglita-
one is the result of improved coronary microvascular
unction related to the favorable effects of the drug on lipid
nd metabolic parameters.
In the present study, the beneficial effect of pioglitazone
n MBF and coronary resistance was observed in the
bsence of changes in plasma glucose or hemoglobin A1c.
his is contrary to the belief that hyperglycemia is a key
odulator of vasodilator function, at least in patients with
iabetes (17,41). The key could be the improved insulin
ensitivity during treatment with pioglitazone, which might
nfluence MBF directly. This is in agreement with a study
howing that nondiabetic insulin-resistant patients manifest
oronary vasomotor abnormalities that can be normalized by
nsulin-sensitizing thiazolidinedione therapy (18). The only
redictor of improvement in endothelial function in this
tudy was the change in fasting plasma insulin level.
urthermore, the recently published PROACTIVE (Pro-
pective Pioglitazone Clinical Trial in Macrovascular
vents) study demonstrated that pioglitazone reduced com-
osite all-cause mortality in patients with type 2 diabetes
hen added to their standard medications. It might be
peculated that, similarly to our study, the benefit observed
n the PROACTIVE study were, at least in part, due to
mprovement in coronary microvascular function (42). In
ine with earlier reports, we observed a significant increase in
diponectin and a decrease in PAI-1 after treatment with
hiazolidinediones (10,43). However, none of the parame-
ers listed in Table 2 showed any significant association with
he changes in MBF or coronary resistance.
tudy limitations. The main limitation of the present
tudy is the relatively small sample size, which, however, was
ufficient to observe highly significant differences between
he 2 groups. We believe that the limited number was
esponsible for some of the differences that were observed in
Figure 3 Hyperemic MBF in Placebo and Pioglitazone
Groups at Baseline and After Treatment
After treatment, a significant increase in hyperemic myocardial blood flow
(MBF) was observed in the pioglitazone group. Error bars indicate SEM. *p 
0.05 within-treatment effect.
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imitation was that only 2 women were enrolled out of 26
atients, although in our experience FCHL is more fre-
uently observed in men. Finally, we did not repeat our
easurements after cessation of treatment and therefore we
annot ascertain if the favorable effects, in particular those
n the coronary circulation, would be long lasting. How-
ver, because PET involves administration of ionizing
adiation, it would have been ethically difficult to justify a
hird scan.
onclusions
he results of this pilot study have demonstrated that the
ddition of pioglitazone to conventional lipid-lowering
herapy in FCHL patients leads to significant beneficial
ffects on metabolic and vascular parameters at both whole
ody and myocardial level beyond those seen with conven-
ional lipid-lowering therapy.
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